These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 34932874)

  • 1. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
    Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
    Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
    Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies.
    Candel FJ; Salavert M; Lorite Mingot D; Manzano Crespo M; Pérez Portero P; Cuervo Pinto R
    Rev Esp Quimioter; 2023 Aug; 36(4):380-391. PubMed ID: 37089055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose.
    Christophorou E; Nilsson AC; Petersen I; Lindvig SO; Davidsen JR; Abazi R; Poulsen MK; Pedersen RM; Justesen US; Johansen NE; Bistrup C; Madsen LW; Johansen IS
    Front Immunol; 2023; 14():1270814. PubMed ID: 38090591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients.
    Sandoval M; Nguyen DT; Huang HJ; Yi SG; Ghobrial RM; Gaber AO; Graviss EA
    PLoS One; 2022; 17(12):e0279222. PubMed ID: 36542654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab.
    Aihara R; Umemura K; Katada Y; Nakagawa S; Kobayashi T; Hatano E; Date H; Nagao M; Terada T
    J Infect Chemother; 2024 Dec; 30(12):1222-1227. PubMed ID: 38777151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
    Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients: The CONTRAST Cohort.
    Bonazzetti C; Tazza B; Gibertoni D; Pasquini Z; Caroccia N; Fanì F; Fornaro G; Pascale R; Rinaldi M; Miani B; Gamberini C; Morelli MC; Tamé M; Busutti M; Comai G; Potena L; Borgese L; Salvaterra E; Lazzarotto T; Scudeller L; Viale P; Giannella M;
    Clin Infect Dis; 2023 May; 76(10):1761-1767. PubMed ID: 36636955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls.
    Vinson AJ; Anzalone AJ; Sun J; Dai R; Agarwal G; Lee SB; French E; Olex A; Ison MG; Mannon RB;
    Am J Transplant; 2022 Oct; 22(10):2418-2432. PubMed ID: 35674237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the Omicron variant truly less virulent in solid organ transplant recipients?
    Anjan S; Khatri A; Viotti JB; Cheung T; Garcia LAC; Simkins J; Loebe M; Phancao A; O'Brien CB; Sinha N; Ciancio G; Vianna RM; Andrews D; Abbo LM; Guerra G; Natori Y
    Transpl Infect Dis; 2022 Dec; 24(6):e13923. PubMed ID: 35915957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
    Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
    Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience in the treatment of COVID-19 with monoclonal antibodies in solid organ transplant recipients.
    Múñez-Rubio E; Calderón-Parra J; Gutiérrez-Villanueva A; Fernández-Cruz A; Ramos-Martínez A
    Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):25-28. PubMed ID: 37997867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.
    Han A; Min S; Jo EA; Lee H; Kim YC; Han SS; Kang HG; Ahn YH; Oh I; Song EY; Ha J
    Ann Lab Med; 2024 Jan; 44(1):64-73. PubMed ID: 37665287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients.
    Linares L; Cofan F; Diekmann F; Herrera S; Marcos MA; Castel MA; Farrero M; Colmenero J; Ruiz P; Crespo G; Llopis J; Garcia-Vidal C; Soriano À; Moreno A; Bodro M;
    PLoS One; 2021; 16(3):e0247251. PubMed ID: 33657157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
    Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study.
    Pereira MR; Arcasoy S; Farr MA; Mohan S; Emond JC; Tsapepas DS; Shi Q; Purpura L; Uhlemann AC; Zucker J; Verna EC
    Transpl Infect Dis; 2021 Aug; 23(4):e13637. PubMed ID: 33993630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
    Bierle DM; Ganesh R; Razonable RR
    J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
    Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
    Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on COVID-19 vaccination in pediatric solid organ transplant recipients.
    Dulek DE; Ardura MI; Green M; Michaels MG; Chaudhuri A; Vasquez L; Danziger-Isakov L; Posfay-Barbe KM; McCulloch MI; L'Huillier AG; Benden C
    Pediatr Transplant; 2022 Aug; 26(5):e14235. PubMed ID: 35060251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.